Public Meeting of the Presidential Commission for the Study of Bioethical Issues, 76042-76043 [2012-31037]
Download as PDF
<![CDATA[
tkelley on DSK3SPTVN1PROD with
76042
Federal Register / Vol. 77, No. 247 / Wednesday, December 26, 2012 / Notices
As a result of its investigation, OSU
has recommended that all of the above
publications be retracted.
Specifically, ORI finds that
Respondent:
• Falsified and/or fabricated Western
blots in an NIH grant application in
three submissions of the same grant
application:
fl Figures 4, 7, 11C: 1 R21 HD058997–
01
fl Figures 7B, 7E, 8B: 1 R21
HD058997–01A1
fl Figures 3C, 3F, 6C: 1 R21
HD058997–01A2
and false Western blots were also
included in Figure 6 in grant
application 1 RC1 HL100298–01.
• Falsified and/or fabricated Western
blots in eighteen (18) figures and in six
(6) published papers. Specifically false
and/or fabricated images were included
in:
fl Figures 2C, 2D, 2F, 3C, 3E, 4G, 5C,
5F: J Biol Chem 285(2):1529–43, 2010
Jan 8
fl Figures 3B, 3C, 3F, 3H, 3I, 3J:
Biochem Biophys Res Commun
370(3):473–7, 2008 Jun 6
fl Figures 2, 3, 4B, 5B, 6, 7B, 8A, 9B:
Am. J. Physiol. Lung Cell. Mol.
Physiol. 293(3):L790–9, 2007 Sept
fl Figure 6: J Biol Chem
282(33):24262–9, 2007 Aug 17
fl Figure 6: Mol Cell Endocrinol 249(1–
2):21–31, 2006 Apr 25
fl Figures 5, 6B, 7B, 9B: Biochim.
Biophys. Acta 1680(3):158–70, 2004
Nov 5.
Dr. Elton has entered into a Voluntary
Exclusion Agreement and has
voluntarily agreed:
(1) To exclude himself from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility or involvement in
nonprocurement programs of the United
States Government referred to as
‘‘covered transactions’’ pursuant to
HHS’ Implementation (2 CFR part 376 et
seq.) of OMB Guidelines to Agencies on
Govermentwide Debarment and
Suspension, 2 CFR part 180 (collectively
the ‘‘Debarment Regulations’’) for a
period of three (3) years, beginning on
November 26, 2012;
(2) To exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant for a period of three (3)
years, beginning on November 26, 2012;
and
(3) To request that the following
publications be retracted:
• J Biol Chem 285(2):1529–43, 2010
Jan 8
VerDate Mar<15>2010
06:31 Dec 22, 2012
Jkt 229001
• Biochem Biophys Res Commun
370(3):473–7, 2008 Jun 6
• J Biol Chem 282(33):24262–9, 2007,
Aug 17
• Mol Cell Endocrinol 249(1–2):21–
31, 2006 Apr 25
• Biochim. Biophys. Acta.
1680(3):158–70, 2004 Nov 5.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
John E. Dahlberg,
Deputy Director, Office of Research Integrity.
[FR Doc. 2012–30866 Filed 12–21–12; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Public Meeting of the Presidential
Commission for the Study of
Bioethical Issues
Department of Health and
Human Services, Office of the Assistant
Secretary for Health, Presidential
Commission for the Study of Bioethical
Issues.
ACTION: Notice of meeting.
AGENCY:
The Presidential Commission
for the Study of Bioethical Issues (the
Commission) will conduct its twelfth
meeting in January. At this meeting, the
Commission will continue discussing
topics related to the ethical issues
associated with the development of
medical countermeasures for children.
DATES: The meeting will take place
Monday and Tuesday, January 14–15,
2013.
SUMMARY:
University of Miami
Hospital Seminar Center, 1400 NW.
12th Avenue, First Floor, Miami,
Florida 33136. Telephone (305) 689–
5511.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Hillary Wicai Viers, Communications
Director, Presidential Commission for
the Study of Bioethical Issues, 1425
New York Avenue NW., Suite C–100,
Washington, DC 20005. Telephone:
202–233–3960. Email:
Hillary.Viers@bioethics.gov. Additional
information may be obtained at
www.bioethics.gov.
Pursuant
to the Federal Advisory Committee Act
of 1972, Public Law 92–463, 5 U.S.C.
app. 2, notice is hereby given of the
twelfth meeting of the Commission. The
meeting will be held from 9 a.m. to
approximately 5 p.m. on Monday,
January 14, 2013, and from 9 a.m. to
approximately 11:45 a.m. on Tuesday,
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
January 15, 2013, in Miami, Fla. The
meeting will be open to the public with
attendance limited to space available.
The meeting will also be webcast at
www.bioethics.gov.
Under authority of Executive Order
13521, dated November 24, 2009, the
President established the Commission.
The Commission is an advisory panel of
the nation’s leaders in medicine,
science, ethics, religion, law, and
engineering. The Commission advises
the President on bioethical issues
arising from advances in biomedicine
and related areas of science and
technology. The Commission seeks to
identify and promote policies and
practices that ensure scientific research,
health care delivery, and technological
innovation are conducted in a socially
and ethically responsible manner.
The main agenda item for the
Commission’s twelfth meeting is to
continue discussing topics related to the
ethical issues associated with the
development of medical
countermeasures for children.
The draft meeting agenda and other
information about the Commission,
including information about access to
the webcast, will be available at
www.bioethics.gov.
The Commission welcomes input
from anyone wishing to provide public
comment on any issue before it.
Respectful debate of opposing views
and active participation by citizens in
public exchange of ideas enhances
overall public understanding of the
issues at hand and conclusions reached
by the Commission. The Commission is
particularly interested in receiving
comments and questions during the
meeting that are responsive to specific
sessions. Written comments will be
accepted at the registration desk and
comment forms will be provided to
members of the public in order to write
down questions and comments for the
Commission as they arise. To
accommodate as many individuals as
possible, the time for each question or
comment may be limited. If the number
of individuals wishing to pose a
question or make a comment is greater
than can reasonably be accommodated
during the scheduled meeting, the
Commission may make a random
selection.
Anyone planning to attend the
meeting who needs special assistance,
such as sign language interpretation or
other reasonable accommodations,
should notify Esther Yoo by telephone
at (202) 233–3960, or email at
Esther.Yoo@bioethics.gov in advance of
the meeting. The Commission will make
every effort to accommodate persons
who need special assistance.
E:\FR\FM\26DEN1.SGM
26DEN1
Federal Register / Vol. 77, No. 247 / Wednesday, December 26, 2012 / Notices
Written comments will also be
accepted in advance of the meeting and
are especially welcome. Please address
written comments by email to
info@bioethics.gov, or by mail to the
following address: Public Commentary,
Presidential Commission for the Study
of Bioethical Issues, 1425 New York
Ave. NW., Suite C–100, Washington, DC
20005. Comments will be publicly
available, including any personally
identifiable or confidential business
information that they contain. Trade
secrets should not be submitted.
Dated: December 17, 2012.
Lisa M. Lee,
Executive Director, Presidential Commission
for the Study of Bioethical Issues.
[FR Doc. 2012–31037 Filed 12–21–12; 4:15 pm]
BILLING CODE 4154–06–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Agency for Healthcare Research
and Quality, HHS.
AGENCY:
ACTION:
Notice.
This notice announces the
intention of the Agency for Healthcare
Research and Quality (AHRQ) to request
that the Office of Management and
Budget (OMB) approve the proposed
changes to the currently approved
information collection project: ‘‘Medical
Expenditure Panel Survey—Insurance
Component.’’ In accordance with the
Paperwork Reduction Act, 44 U.S.C.
3501–3521, AHRQ invites the public to
comment on this proposed information
collection.
SUMMARY:
Comments on this notice must be
received by February 22, 2013.
DATES:
Written comments should
be submitted to: Doris Lefkowitz,
Reports Clearance Officer, AHRQ, by
email at doris.lefkowitz@AHRQ.hhs.gov.
Copies of the proposed collection
plans, data collection instruments, and
specific details on the estimated burden
can be obtained from the AHRQ Reports
Clearance Officer.
tkelley on DSK3SPTVN1PROD with
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427–1477, or by
email at doris.lefkowitz@AHRQ.hhs.gov.
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
06:31 Dec 22, 2012
Jkt 229001
Proposed Project
Medical Expenditure Panel Survey—
Insurance Component
Employer-sponsored health insurance
is the source of coverage for 85 million
current and former workers, plus many
of their family members, and is a
cornerstone of the U.S. health care
system. The Medical Expenditure Panel
Survey—Insurance Component (MEPS–
IC) measures the extent, cost, and
coverage of employer-sponsored health
insurance on an annual basis. Private
industry statistics are produced at the
National, State, and sub-State
(metropolitan area) level and State and
local government statistics at the
National and Census Region level.
Statistics are also produced for State
and Local governments. The MEPS–IC
was last approved by OMB on December
12th, 2012 and will expire on December
31st, 2014. The OMB control number for
the MEPS–IC is 0935–0110. All of the
supporting documents for the current
MEPS–IC can be downloaded from
OMB’s Web site at https://
www.reginfo.gov/public/do/
PRAViewDocument?ref_nbr=2011100935-001.
The current MEPS–IC clearance noted
the possibility of making changes to the
2013 MEPS–IC survey in order to
address data needs for Patient
Protection and Affordable Care Act
(PPACA) and other issues. AHRQ
solicited input on possible new
questions from a working group of over
50 individuals that included multiple
representatives from the U.S.
Department of Health and Human
Services’ Assistant Secretary for
Planning and Evaluation (ASPE), the
Center for Medicare & Medicaid
Services’ (CMS) Center for Consumer
Information and Insurance Oversight,
the CMS Office of the Actuary, the
National Center for Health Statistics, the
President’s Council of Economic
Advisors, the Office of Management and
Budget, the Bureau of Labor Statistics,
the Employee Benefits Security
Administration, and the Bureau of the
Census.
After the working group agreed on a
reasonable number of specific questions,
the Bureau of the Census, at AHRQ’s
direction, conducted a pretest of these
questions on a sampled set of 2012
MEPS–IC survey respondents. A
telephone pretest was conducted in the
spring and summer of 2012. The results
of this pretest, conducted under the
Census Bureau’s generic pretest
clearance process, led to AHRQ
recommending that a subset of the
tested questions be added to the survey
in 2013. To avoid increasing the overall
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
76043
burden on survey respondents, a
proportional number of questions have
been proposed for deletion. Questions
identified for deletion were those with
limited analytic value and/or belowaverage response rates. The AHRQ
recommendations were accepted by the
HHS Data Council in November 2012.
For all establishment-level MEPS–IC
forms, AHRQ proposes to make the
following changes to questions asked of
employers who offer health insurance:
Additions
• Did your organization offer health
insurance to unmarried domestic
partners of the same sex? Yes/No/Don’t
Know
• Did your organization offer health
insurance to unmarried domestic
partners of the opposite sex? Yes/No/
Don’t Know
Deletions
• For 2013, what was the TYPICAL
waiting period before new employees
could be covered by health insurance?
Less than 2 weeks/2 weeks to less than
1 month/Until the first day of the next
month/1–3 months/More than 3 months
• Did your organization place any
limits or restrictions on health
insurance coverage for the spouse of an
employee if the spouse had access to
coverage through another employer?
Yes/No/Don’t Know
For all plan-level MEPS–IC forms,
AHRQ proposes to make the following
changes:
Additions
• (For self-insured health plans that
purchase stop-loss coverage) What is the
specific stop-loss coverage amount per
employee? $lll.00
• Did the premiums for this insurance
plan vary by any of these
characteristics? Smoker/non-smoker
will be added to current list of Age,
Gender, Wage or Salary levels, and
Other. The ‘‘Premiums did not vary’’
response checkbox will be deleted and
replaced with Yes/No/Don’t Know
responses for each characteristic.
• Did the amount an employee
contributed toward his/her own
coverage vary by any of these employee
characteristics? Participation in a
fitness/weight loss program and
participation in a smoking cessation
program will be added to the current list
of Hours worked, Union status, Wage or
salary level, Occupation, Length of
employment, and Other. The ‘‘Employee
contribution did not vary’’ response
checkbox will be deleted and replaced
with Yes/No/Don’t Know responses for
each characteristic.
E:\FR\FM\26DEN1.SGM
26DEN1
]]>Agencies
[Federal Register Volume 77, Number 247 (Wednesday, December 26, 2012)]
[Notices]
[Pages 76042-76043]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-31037]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Meeting of the Presidential Commission for the Study of
Bioethical Issues
AGENCY: Department of Health and Human Services, Office of the
Assistant Secretary for Health, Presidential Commission for the Study
of Bioethical Issues.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: The Presidential Commission for the Study of Bioethical Issues
(the Commission) will conduct its twelfth meeting in January. At this
meeting, the Commission will continue discussing topics related to the
ethical issues associated with the development of medical
countermeasures for children.
DATES: The meeting will take place Monday and Tuesday, January 14-15,
2013.
ADDRESSES: University of Miami Hospital Seminar Center, 1400 NW. 12th
Avenue, First Floor, Miami, Florida 33136. Telephone (305) 689-5511.
FOR FURTHER INFORMATION CONTACT: Hillary Wicai Viers, Communications
Director, Presidential Commission for the Study of Bioethical Issues,
1425 New York Avenue NW., Suite C-100, Washington, DC 20005. Telephone:
202-233-3960. Email: Hillary.Viers@bioethics.gov. Additional
information may be obtained at www.bioethics.gov.
SUPPLEMENTARY INFORMATION: Pursuant to the Federal Advisory Committee
Act of 1972, Public Law 92-463, 5 U.S.C. app. 2, notice is hereby given
of the twelfth meeting of the Commission. The meeting will be held from
9 a.m. to approximately 5 p.m. on Monday, January 14, 2013, and from 9
a.m. to approximately 11:45 a.m. on Tuesday, January 15, 2013, in
Miami, Fla. The meeting will be open to the public with attendance
limited to space available. The meeting will also be webcast at
www.bioethics.gov.
Under authority of Executive Order 13521, dated November 24, 2009,
the President established the Commission. The Commission is an advisory
panel of the nation's leaders in medicine, science, ethics, religion,
law, and engineering. The Commission advises the President on
bioethical issues arising from advances in biomedicine and related
areas of science and technology. The Commission seeks to identify and
promote policies and practices that ensure scientific research, health
care delivery, and technological innovation are conducted in a socially
and ethically responsible manner.
The main agenda item for the Commission's twelfth meeting is to
continue discussing topics related to the ethical issues associated
with the development of medical countermeasures for children.
The draft meeting agenda and other information about the
Commission, including information about access to the webcast, will be
available at www.bioethics.gov.
The Commission welcomes input from anyone wishing to provide public
comment on any issue before it. Respectful debate of opposing views and
active participation by citizens in public exchange of ideas enhances
overall public understanding of the issues at hand and conclusions
reached by the Commission. The Commission is particularly interested in
receiving comments and questions during the meeting that are responsive
to specific sessions. Written comments will be accepted at the
registration desk and comment forms will be provided to members of the
public in order to write down questions and comments for the Commission
as they arise. To accommodate as many individuals as possible, the time
for each question or comment may be limited. If the number of
individuals wishing to pose a question or make a comment is greater
than can reasonably be accommodated during the scheduled meeting, the
Commission may make a random selection.
Anyone planning to attend the meeting who needs special assistance,
such as sign language interpretation or other reasonable
accommodations, should notify Esther Yoo by telephone at (202) 233-
3960, or email at Esther.Yoo@bioethics.gov in advance of the meeting.
The Commission will make every effort to accommodate persons who need
special assistance.
[[Page 76043]]
Written comments will also be accepted in advance of the meeting
and are especially welcome. Please address written comments by email to
info@bioethics.gov, or by mail to the following address: Public
Commentary, Presidential Commission for the Study of Bioethical Issues,
1425 New York Ave. NW., Suite C-100, Washington, DC 20005. Comments
will be publicly available, including any personally identifiable or
confidential business information that they contain. Trade secrets
should not be submitted.
Dated: December 17, 2012.
Lisa M. Lee,
Executive Director, Presidential Commission for the Study of Bioethical
Issues.
[FR Doc. 2012-31037 Filed 12-21-12; 4:15 pm]
BILLING CODE 4154-06-P
